Cephadol

Quick links to important sections

Cephadol

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cephadol

Cephadol: Identity, Composition, and General Purpose

Property Description
Active Ingredient Difenidol hydrochloride
Primary Form Oral tablets
Pharmacological Class Antiemetic and Antivertigo Agent
General Purpose Relieves dizziness, vertigo, nausea, and vomiting
Origin Synthetic (Tertiary Alcohol Derivative)

Cephadol is a pharmaceutical preparation defined by its active chemical entity, Difenidol hydrochloride. This medication is classified primarily as an antiemetic agent and an antivertigo agent, reflecting its intended use for relieving disturbances in balance and controlling the reflex actions that cause nausea and vomiting. The drug is typically prepared for oral administration as tablets, although it is also manufactured as an injectable solution for parenteral routes.

The core substance is synthetic, a tertiary alcohol derivative, ensuring a consistent chemical profile. This single-ingredient product’s therapeutic action is entirely concentrated in the effects of Difenidol.


Classification and Functional Principle

The formal classification of Cephadol positions it as both an antiemetic agent and an antivertigo agent. This dual functionality is vital, as it indicates the drug targets both the gastric distress (antiemetic) and the inner ear disturbances (antivertigo) that often occur concurrently.

A key differentiating factor for Difenidol is its muscarinic antagonist action, which involves an anticholinergic effect that sets its mechanism apart from anti-nausea medications acting solely on other neurotransmitter systems. Difenidol’s mechanism involves depressing the labyrinthine function. This action means the medicine works by quieting the overactive signals sent from the inner ear that often cause spinning and disequilibrium. This dual functional principle provides a comprehensive functional benefit: stabilizing the body's perception of balance and interrupting the reflex arc that triggers emesis.

What side effects are possible with Cephadol?

Possible Side Effects and Safety Information

The official regulatory safety profile of Cephadol (Difenidol) classifies adverse reactions based on their frequency and the physiological systems affected, consistent with its primary pharmacological activity. The adverse events are predominantly linked to effects on the Central Nervous System (CNS) and Anticholinergic action.

Documented Adverse Reactions

The most frequently reported side effects documented in regulatory labeling are often related to CNS depression and include drowsiness and blurred vision. Other less common reactions classified within the official documents affect multiple systems, including dry mouth, dizziness, headache, heartburn, and unusual tiredness.

System-Organ Class Examples of Documented Effects
Nervous/Psychiatric Drowsiness, Dizziness, Headache, Nervousness
Gastrointestinal Dry mouth, Heartburn, Stomach upset or pain
Ocular Blurred vision

Serious Reactions and Safety Constraints

Rare but clinically significant adverse reactions are documented, including confusion and hallucinations, which have been reported to occur within the first few days of therapy. The official labeling notes that these symptoms generally resolve within three days of stopping the medicine. Tachycardia (palpitation) is also listed as a rare effect.

Specific safety-related restrictions exist based on the drug's properties. Cephadol is generally contraindicated in patients with severe renal impairment due to the risk of drug accumulation. Additionally, due to its anticholinergic activity, it should not be used in individuals with conditions such as Glaucoma or Gastrointestinal/Urinary tract obstruction (e.g., enlarged prostate), as these conditions may be exacerbated.

Overdose and Emergency Response

The official regulatory documents detail the severe clinical signs and required emergency actions associated with a Cephadol (Difenidol hydrochloride) overdose. Overdose exposure requires immediate professional attention due to the potential for life-threatening complications.

Documented Overdose Manifestations Severe Outcomes & Actions Required
Severe Drowsiness or Somnolence Risk of Coma and Seizures
Troubled Breathing or Shortness of Breath Risk of Respiratory Depression and failure
Severe Unusual Tiredness or Weakness Risk of severe Hypotension

When to Seek Urgent Medical Help Immediate medical attention must be sought for any instance of overdose exposure. Specifically, troubled breathing or severe drowsiness necessitate urgent care. The official instructions mandate contacting a Poison Control Center for guidance on managing the overdose or unintentional ingestion. For cases involving suspected intentional overdose, referral for a psychiatric consultation is required.

Official Management and Specific Risk Management for Cephadol overdose is defined as essentially supportive, as no specific antidote is documented in the labeling. Supportive measures explicitly include the maintenance of blood pressure and maintenance of respiration. Furthermore, official regulatory information carries a warning that Difenidol overdose may result in serious toxicity in children. The protocol requires careful observation of the patient, and early gastric lavage may be indicated depending on the ingested amount and the patient's symptoms.

Therapeutic Uses of Cephadol

Quick Facts

Therapeutic Domain Conditions Addressed
Antiemetic and Antivertigo Nausea, vomiting, dizziness, peripheral (labyrinthine) vertigo, Ménière's disease.

Understanding Cephadol's Therapeutic Uses

Cephadol is a pharmaceutical agent primarily indicated for controlling and preventing nausea, vomiting, and dizziness. It is used to manage these symptoms when they arise from various medical issues, particularly those involving inner ear disturbance or labyrinthine dysfunction.

Main Uses and Clinical Benefits

Cephadol is frequently utilized in the following clinical scenarios:

  • Vertigo and Dizziness: The drug is used to diminish vestibular stimulation, which helps in the symptomatic treatment of peripheral vertigo. This includes managing episodes related to conditions such as Ménière's disease.
  • Nausea and Vomiting Control: It provides a therapeutic benefit by helping to control nausea and vomiting that may be associated with various causes, including postoperative states and labyrinthine disturbances. Its action is thought to involve depressing labyrinthine function and affecting the medullary chemoreceptive trigger zone.

The medication is used in these domains, including the symptomatic management of inner ear disorders like Ménière's disease.

Regulatory References

  1. NIH MedlinePlus guidance

Eligibility and Restrictions for Use

Who Can and Cannot Use Cephadol?

The eligibility for using Cephadol (Difenidol hydrochloride) is strictly governed by regulatory requirements, which define patient populations that are prohibited from use and those that require special caution.

Absolute Prohibitions (Contraindications)

This medication must not be used by individuals with the following conditions:

  • Glaucoma or Anuria (renal shutdown).
  • Obstructive Diseases of the gastrointestinal or genitourinary tracts (e.g., prostatic hypertrophy, pyloric obstruction).
  • Known allergy or hypersensitivity to Difenidol hydrochloride.

Age and Physiological Restrictions

Population Eligibility Status
Infants Contraindicated in those under 6 months old.
Children Not recommended for children weighing less than 22.8 kg.
Elderly Use requires special caution and monitoring.
Pregnancy Not indicated for nausea/vomiting of pregnancy; use only if clearly needed.
Breastfeeding Use requires assessment, as safety data is insufficient.

Conditional Use

Cephadol requires caution and monitoring for patients with renal impairment (due to risk of drug accumulation), low blood pressure (hypotension), or a stomach ulcer.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Cephadol (Difenidol hydrochloride) primarily through pharmacodynamic interactions and conditions that alter systemic drug clearance.


Documented Interaction Patterns

The co-administration of Cephadol with certain substances leads to additive or potentiated effects, as noted in prescribing information:

  • Central Nervous System (CNS) Depressants (e.g., narcotics, sedatives, tranquilizers, certain antihistamines): Co-administration will add to the depressant effects of these medicines.
  • Alcohol: Consumption of alcohol will also add to the depressant effects of Difenidol.
  • Anticholinergic Agents: The effects of other agents with anticholinergic activity may be potentiated when used concurrently.

Restrictions and Population-Specific Notes

Interactions are also restricted by specific patient conditions affecting clearance:

  • Renal Impairment: Conditions such as kidney disease or anuria may lead to higher blood levels of Difenidol, which increases the chance of systemic accumulation and associated effects.
  • Obscured Symptoms: The antiemetic action of Cephadol is officially documented as having the potential to mask signs of overdose of other toxic drugs (e.g., digitalis) and to obscure the diagnosis of certain conditions, such as intestinal obstruction.

Mechanism of Action

Cephadol (Diphenidol) is a pharmacologic agent whose effects are primarily mediated through muscarinic acetylcholine (mACh) receptor antagonism. The compound functions as a non-selective antagonist at central and peripheral mACh receptor subtypes, including M1, M2, M3, and M4, to modify cholinergic signaling.

In the central nervous system, Cephadol targets the vestibular nuclei and the chemoreceptor trigger zone (CTZ), both located in the brainstem. Antagonism of mACh receptors at the vestibular nuclei modulates neural activity and stabilizes afferent transmission from the labyrinthine structures. Similarly, antagonism within the CTZ influences neurotransmission pathways involved in central signaling. These molecular interactions result in a downstream depression of labyrinthine function and modification of efferent vestibulocerebellar pathways. The system-level physiological consequence is a reduction in abnormal signal input from the vestibular system.

Dosage and Administration Information

Cephadol (Difenidol) is administered via the oral route using tablets, or parenterally through intramuscular (IM) or intravenous (IV) injection, depending on the patient's clinical state. For adult oral administration, the typical starting dose is 25 mg to 50 mg per dose, taken every four hours as needed for symptomatic control. The total amount administered must not exceed 300 mg in any 24-hour period.

Administration frequency for the oral tablets is typically every four hours (q4h). If the medicine is being taken to help prevent symptoms, it may be administered with food, water, or milk to help minimize potential gastric irritation. Conversely, if active nausea and vomiting are already present, the drug is best taken with only a small amount of water.

Population-Specific Use

Dosing for pediatric patients is not based on a fixed adult dose but must be calculated by body weight, commonly at approximately 0.88 mg/kg per unit dose. This weight-based calculation ensures adherence to the maximum daily limit of 5.5 mg/kg. The injectable solution is not recommended for use in children. The initial use of Cephadol is limited to patients who are under continuous, close professional supervision.

Missed Dose Instructions

If a scheduled dose is missed, it should be taken as soon as it is remembered. However, if the time for the next scheduled dose is nearly approaching, the missed dose should be skipped entirely, and the regular schedule resumed. A double dose must never be taken to compensate for the skipped dose.

Recent Clinical Evidence

Research evidence / Overview of studies for Cephadol


Evidence for Use in Peripheral Vertigo and Dizziness

Research was studied in research exploring how symptoms change over time related to peripheral (labyrinthine) vertigo and dizziness. Studies were evaluated in adult patients presenting with symptoms related to inner ear balance issues. The research monitored outcomes related to systemic or functional imbalance, as well as patient-reported outcomes describing perceived discomfort.

Studies monitored objective measures like equilibrium function and caloric response. Findings describe patterns observed in the studies related to these measured outcomes compared to control arms, which included placebo or other comparators. However, the overall research base is considered moderate in strength, and evidence is limited concerning the consistency of findings. Sample sizes were modest in older trials, and evidence quality varies across studies.


Evidence for Use in Nausea and Vomiting Control

Cephadol was studied for research exploring short-term symptom changes related to nausea and vomiting, particularly in acute or disruptive episodes like postoperative states. Research explored short-term use, focusing on short-term symptom changes in adult populations. Studies monitored key outcomes related to physical discomfort, which included the reported frequency of vomiting episodes and subjective feelings of nausea. Data show patterns related to the monitored changes in these symptoms in the acute timeframe.

Comparative evidence is lacking when assessing Cephadol against the full range of modern antiemetic options in all possible clinical scenarios. The scientific literature often notes that the findings were mixed or derived from older studies, and there are limitations concerning comparison in more complex or prolonged antiemetic treatment regimens.


Long-Term Research and Study Duration

Research for both indications studies focusing on episodes where symptoms become more noticeable. Consequently, the follow-up durations were limited, typically focusing on immediate or acute symptom relief, such as an observation period of a few weeks. The limited follow-up durations mean there is limited information for long-term outcomes regarding the sustained use of Cephadol, and long-term effects are not fully established.


Key Uncertainties and Research Gaps

This section synthesizes the areas where certainty remains low. Evidence is limited by the lack of recent, large-scale randomized controlled trials (RCTs) that follow current methodological standards. Research provides context but not individual predictions, as findings describe group patterns, not personal outcomes. Because evidence quality varies across studies, the overall findings are sometimes mixed. This indicates an overall need for more defined data to address current clinical standards.

Frequently Asked Questions (FAQ)

Common questions about Cephadol (FAQ)


Q: How long does it take for Cephadol to start working after taking a dose?

According to official product information, the active ingredient in Cephadol reaches its maximum concentration in the blood approximately 1.5 to 3 hours after an oral dose. This time frame represents when the drug concentration is measured to be highest in the blood, according to studies.


Q: Can I take Cephadol with food?

Official information indicates that Cephadol may be taken with food, water, or milk, especially when it is being used to prevent symptoms. This is noted as a strategy to help minimize potential gastric (stomach) irritation.


Q: Does Cephadol interact with all anticholinergic drugs?

Regulatory documents state that the effects of other agents with anticholinergic activity may be potentiated when used concurrently with Cephadol. The potential for increased effects means that using Cephadol alongside other anticholinergic agents requires professional guidance.

How should Cephadol be stored and disposed of?

How to Store and Dispose of Cephadol?

Regulatory guidelines define specific conditions necessary for maintaining the stability and safety of Cephadol tablets.

Official Storage Requirements

The medicine must be stored at room temperature and kept in a closed, tightly sealed container. It is mandated that Cephadol be protected from environmental factors, specifically moisture, excessive heat, and direct light. The product must not be frozen.

Child Safety and Disposal

The official label requires that Cephadol must be stored out of the sight and reach of children. For unused or expired product, the standard disposal instruction is to utilize a drug take-back program. If a take-back program is unavailable, federal guidelines advise mixing the medicine with an undesirable substance before sealing it for disposal in the household trash. It is explicitly prohibited by regulation to flush the tablets down the sink or toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cephadol found in:

A-Z Index: